Our Vision

Using AHR precision diagnostics we will become a leading provider to improve response to cancer immunotherapy by 2026

Effective patient stratification

AHR profiles highlight patient potential for treatment & response

Increase of clinical trial success

AHR activity segments Lung Cancer (survival) independent of CDx (PD-L1)

Utility for many drugs in many tumors

We have validated the AHR signature in many cancers with many modulators

Our Know-How

We extensively profiled multiple activators of the AHR and the subsequent transcriptional responses across multiple tissues and cancers.

BIOINFORMATICS PLATFORM

Our bioinformatics platform analyses  high throughput data for AHR activation and functions from gene expression, proteome and metabolome data.

LEARN MORE

AHR SIGNATURE DATABASE

We possess a broad database of AHR signatures. This database enables us to investigate AHR activity in cancer and autoimmune diseases.

LEARN MORE

CDx DEVELOPMENT

We perform studies for biomarker verification, validation and CDx development in AHR-related therapeutic development programs .

LEARN MORE
Science and Technology

Our Solution:
Universal AHR-signature

Overcomes cell and ligand type specificity
Validated in 32 cancers
Transferable across multi-omics layers

Read more

Our business model

BusinessModel

Contact us for more information

IR@cAHRmeleon.com